{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:43:29Z","timestamp":1768448609240,"version":"3.49.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.pbj.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T03:00:26Z","timestamp":1489201226000},"page":"81-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost\u2013utility analysis"],"prefix":"10.1097","volume":"2","author":[{"given":"Jo\u00e3o","family":"Peres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Delgado","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210317","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"R2-4-20210317","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician.","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R3-4-20210317","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis.","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"R4-4-20210317","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis.","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"R5-4-20210317","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis - experience from five patients.","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"R6-4-20210317","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study.","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"key":"R7-4-20210317","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"R8-4-20210317","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant.","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"R9-4-20210317","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"R10-4-20210317","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14712598.2013.767329","article-title":"Monoclonal antibodies in neuroinflammatory diseases.","volume":"13","author":"Klotz","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"R11-4-20210317","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/heartjnl-2015-308255","article-title":"QALYs in cost-effectiveness analysis: an overview for cardiologists.","volume":"101","author":"Wouters","year":"2015","journal-title":"Heart"},{"key":"R12-4-20210317","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"Composite: a valid and reliable outcome measure for myasthenia gravis.","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"R13-4-20210317","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"R14-4-20210317","doi-asserted-by":"crossref","first-page":"664","DOI":"10.20344\/amp.1317","article-title":"Contribution for the validation of the Portuguese version of EQ-5D.","volume":"26","author":"Ferreira","year":"2013","journal-title":"Acta Med Port"},{"key":"R15-4-20210317","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"R16-4-20210317","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hec.901","article-title":"Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.","volume":"13","author":"Richardson","year":"2004","journal-title":"Health Econ"},{"key":"R18-4-20210317","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.","volume":"201-","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R19-4-20210317","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis.","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2444866416301507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2444866416301507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1016\/j.pbj.2017.02.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T23:15:00Z","timestamp":1658790900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02054639-201705000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.pbj.2017.02.002","relation":{},"ISSN":["2444-8664"],"issn-type":[{"value":"2444-8664","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost\u2013utility analysis","name":"articletitle","label":"Article Title"},{"value":"Porto Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.pbj.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 PBJ-Associa\u00e7\u00e3o Porto Biomedical\/Porto Biomedical Society. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}